BOINC.Italy
La community italiana dedicata al calcolo distribuito
Gli amministratori del progetto hanno presentato la nuova fase 2 del progetto che partirà a breve.
Nuovi tools, nuovi collaboratori e nuove tecniche di cura saranno a disposizione del team.
Maggiori info qui
Anche fosse 1 caso ogni cent'anni, secondo me ha diritto a una cura.Praticamente le case farmaceutiche non sono molto interessate a sostenere i costi della ricerca perchè il mercato è ristretto.
Mavaff
PS : mi sembra che questi istituti giappo siano molto interessati al WCG di IBM
[...]In Phase 2, we will be examining a wider range of target childhood cancers, to include other cancers of the liver and bones. So our initial efforts in Phase 2 will target hepatoblastoma and Ewing’s sarcoma as well as neuroblastoma. Other cancers will be added later as specific protein targets are identified and their structures discovered.
In a previous update, one of the problems we mentioned is that many pharmaceutical companies are not interested in developing drugs for neuroblastoma, because the potential market is relatively small. That’s why we are especially excited to announce that recently, two organizations that support drug development in Japan - the National Institute of Biomedical Innovation (NIBIO) and the Innovation Network Corporation of Japan (INCJ) - have shown interest in our project of TrkB antagonists as candidate anti-cancer drugs
